Atlas Trials

MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

Clinical trial NCT04834024 · RECRUITING

Trial details

NCT number
NCT04834024
Sponsor
Beijing Mabworks Biotech Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Follicular Lymphoma and Marginal Zone Lymphoma
Start date
2021-06-02
Primary completion
2025-03-01
Enrollment
168

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.